CHAPTER 3 | Intracellular signalling controlled by the endosomal-exosomal pathway

Frederik J. Verweij, Jaap M. Middeldorp and D. Michiel Pegtel
Tight control of intracellular signalling is essential for developmental processes such as cell differentiation, migration but also to maintain tissue homeostasis. Disruption in the control of these signalling pathways can result in cell death (apoptosis), anergy or promote uncontrolled proliferation leading to cancer. Proper termination of signalling is thus equally important as initiation. Well-known pathways for downregulating receptor signalling involve regulation on the pre- and post transcriptional level and subsequently lysosomal, proteosomal, or autophagosomal degradation of these proteins. An alternative pathway for attenuating intracellular signalling was recently discovered independently by the group of M. Caplan and our own group. It appears that apart from classical protein degradation, the release of signalling proteins controls at least two major signal transduction routes namely the canonical Wnt/β-catenin and NFκB pathways. Expelling proteins from the cell, rather than the co-ordinated degradation in lysosomes may also involve defined protein modifications, such as ubiquitination, myristylation, and/or palmitoylation, but little experimental data is available. Although the secretion of proteins via exosomes starts by accumulation within multivesicular bodies (MVBs), a key distinction with degredatory MVBs is that exosome-producing MVBs seem to preferentially fuse with the plasma membrane. Here we discuss the latest developments in exosomes biology in relationship to signal transduction control.

Introduction

Exosomal discharge as a novel mechanism for signalling attenuation

Latent membrane protein-1 (LMP1) is considered the main oncoprotein encoded by the human tumor virus Epstein-Barr (EBV) as it has classic transforming activity in rodent fibroblasts. LMP1 is a constant firing signalling-homologue of human CD40, which biological function is to ensure efficient maturation of naive B-cells into long-lived memory B-cells. Antibody affinity maturation is driven primarily by competition for T cell help, indicating that interactions between CD40-ligand expressed on T cell and CD40 on B cells is crucial for memory B cell development. Interestingly, these memory B cells are the ultimate hiding-place for latent EBV infection in humans when no viral genes are expressed except occasionally EBNA-1. LMP1 contains six transmembrane regions that mediate trafficking and intermolecular (self)aggregation which are required for initiating downstream signaling via recruitment of TNF receptor-associated factors (TRAF) at the cytoplasmic C-terminus. In vitro, LMP1 expression is critical for efficient transformation of naive B-cells by inducing constitutive NFκB activation upon infection. Chronic NFκB activation may have oncogenic consequences and drives the continuous proliferation of EBV-infected lymphoma cells. The oncogenic and growth-promoting properties of LMP1 are directly associated with its ability to signal without a ligand. Forced mono-ubiquitylation at the N-terminus of LMP1 leads to a strong increase in LMP1 breakdown, but does not result in strikingly attenuated NFκB activation, suggesting alternative regulatory pathways that are functional apart from classic proteasomal and lysosomal degradation. Indeed we recently discovered that endosome driven release of LMP1 via exosomes, chaperoned
CHAPTER 3

by the tetraspanin family member CD63, strongly reduces LMP1-mediated NFκB signalling. Knock-down of CD63 by short hairpin RNAs (RNAi) against CD63, lead to sequestering of LMP1 protein in intracellular compartments and reduced LMP1 release through exosomes that strongly increased NFκB activation. CD63 belongs to the evolutionary conserved family of tetraspanins proteins that assemble in tiny membranous platforms that guide intracellular trafficking of their associated-partners.

Figure 1 | Model for LMP1 trafficking and signalling as compared to EGFR
Model that highlights the distinction between latent membrane protein 1 (LMP1, in blue) trafficking via multivesicular bodies (MVB) into exosomes and Endothelial Growth Factor Receptor (EGFR, in red) trafficking and degradation in lysosomes. (1) LMP1 is synthesized in the ER and traffics through the Golgi (G). Subsequently, LMP1 traffics to and accumulates in microdomains of the limiting membrane (LM) of multivesicular bodies (MVBs). Inward budding of microdomains that contain LMP1 form intraluminal vesicles (ILVs). (2) ILVs that contain LMP1 are secreted as exosomes upon fusion of the LM with the plasma membrane (PM). In all steps from Golgi to LM the C-terminus of LMP1 that mediates NF-kB signaling is exposed to the cytoplasm. EGFR in contrast traffics to the plasma membrane (A), is ubiquitinated and internalized in early endosomes (B). A fraction is re-expressed at the PM via recycling endosomes (C), the remainder is incorporated in MVBs (D) and targeted for degradation (E) by fusion with lysosomes (L). Both PM associated and internalized EGFR signal after EGF binding.
Thus EBV encoded LMP1 may have co-opted the physiological role of CD63 in human B cells for its own benefit.

In a conceptually similar study, Chairoungdua et al. reported on the crucial involvement of tetraspanins in the Wnt signal-transduction pathway. Wnt proteins are a group of secreted, lipid-modified, signaling glycoproteins ranging between 350-400 amino acids in length. Wnt binds co-receptors Frizzled (FRZ) and low-density lipoprotein receptor-related protein (LRP) 5/6, resulting in the activation of the Dishevelled (Dvl) protein, which then prevents Glycogen Synthase Kinase 3β (GSK3β)–
mediated phosphorylation and subsequent degradation of $\beta$-catenin. As a result, $\beta$-catenin accumulates in the cytosol and translocates to the nucleus where it binds to the transcription factors T-cell factor (TCF) and lymphoid enhancer factor (LEF). Activation of TCF/LEF results in direct binding to Wnt responsive elements (WREs) and the activation of target gene expression, including Met, a proto-oncogene encoding the tyrosine kinase receptor for HGF\(^9\). Gene expression resulting from Wnt signaling and cross-talk with other factors ultimately drive cell fate decisions, including proliferation/survival activities and changes in cell shape\(^10\). Therefore, it is not surprising that there is a clear link between aberrant Wnt-signaling and cancer, mediated by stabilized $\beta$–catenin in the cytoplasm and increased translocation to the nucleus\(^11\). Thus, exosomal secretion of the $\beta$-catenin via the E-cadherin complex to inhibit Wnt signaling, may be an effective alternative method to prevent overstimulation. Provocatively, this effect was enhanced by exogenous expression of the tetrspanins CD82 and CD9 (but not CD63) suggesting that tetrpanins are important for the proper (down) regulation of Wnt signaling by mediating endosomal trafficking and secretion via exosomes\(^2\), similar to the role of CD63 in LMP1-mediated NF$\kappa$B activation as we described in B cells.

Tetraspanins

Tetraspanins in exosomes

Tetraspanins are a major class of proteins in exosomes secreted by multiple cell-types\(^12\), indicating a tight link between the exosomal pathway and this family of scaffolding proteins. Tetraspanins may function by selectively collecting partner proteins for incorporation into exosomes at endolysosomal membranes. Indeed, apart from LMP1 and $\beta$-catenin, other proteins that are secreted via exosomes also seem closely associated with tetrspanins such as the common HLA-DR molecule expressed in immune cells\(^13\). Whether tetraspanins have a role in the actual biogenesis of exosomes at the limiting membrane of endosomes is unclear. Possibly, inward budding of the limiting membrane of MVBs is potentiated by tetrspanins microdomains (TEMs) to form ILVs. TEMs may vary in size ranging from micro- to nanometer scale, depending on the techniques used. Such detailed distinctions are possibly important for our understanding on the biology of endosome-derived exosomes. Neither is it clear whether specificity for targeting of (lipid) microdomains to different “classes” of MVBs exist. Despite a lack of experimental evidence, distinct mechanisms for ILV biogenesis have been proposed\(^14\). These could also play a role in the diversification between MVBs that are destined to fuse with lysosomes for degradation or those that preferentially fuse with the plasma membrane for release of cargo via exosomes. Whether the latter “class” of MVBs will contain mixed populations of ILVs or whether there might be a further diversification into “sub-classes” of MVBs remains uncertain. However, if one assumes that all secreted exosomes are biologically functional, simultaneous release of mixed ILV populations from a single MVB, seems incompatible with the presumed targeted effects of exosomes in local microenvironments\(^15,16\). Thus, increasing selectivity of exosome function in vivo maybe more efficient when creating similar ILV in distinct subclasses of MVBs. Possibly
pathogens such as EBV may disturb such coordinated release of functional exosomes by insertion of its own viral gene products.\textsuperscript{1,17}

**Tetraspanin modifications**

Members of the tetraspanin superfamily are characterized by four transmembrane spanning domains, a small (EC1) and a large (EC2) extracellular loop with a highly conserved ‘CCG’ motif. CD9, CD63, and CD82 are glycosylated and can be palmitoylated at their juxtamembrane cysteine residues. CD63 is differentially glycosylated during maturation steps of immune cells.\textsuperscript{18} Glycosylation and most myristoylation modifications are irreversible and function by promoting protein integrity and guiding proper intracellular trafficking. Palmitoylation is distinct as it is reversible in nature and may specifically contribute to the organization and flexibility of the tetraspanin-web.\textsuperscript{19} This web of tetraspanin scaffolds facilitates proteins in temporal as well as spatial engagement into a diversity of microdomains, and is thereby of structurally importance for proper protein trafficking and signaling.

**(Late-)endosomes in signalling**

From a signalling perspective, late endosomes/MVBs are convenient intracellular compartment for regulatory purposes as these compartments may allow “back-fusion” of ILVs with the limiting membrane. Signaling molecules stored in ILVs of MVBs are presumably inactive as they active signaling sites are not in contact with the cytosol, but upon back-fusion, may become immediately accessible. Moreover being packed already in small domains may facilitate signalling initiation as well. Currently back-
fusion in MVBs has only been described for invading infectious agents and thus concerns entry, rather then re-entry of the cytosol\cite{20,21}. The process of back-fusion might be facilitated by local concentrations of specific lipids such as lysobisphosphatidic acid (LBPA) and/or its putative effectors Alix and/or tetraspanins CD9 and CD81 known to mediate membrane fusion events\cite{14,22}. A delicate balance between inward budding and back-fusion of ILVs/TEMs would allow precise and defined localized control over signaling potency. Alternatively, back-fusion may enable MVBs to function as a repository for proteins needed for acute responses, i.e. temporary storage for signaling receptors, which may allow rapid adjustment to changing environments. (Figure 1). So far systematic studies into the endocytic pathway showed that mTORC1 signals from MVBs\cite{23}, and a recently proposed model for Notch activation by Delta assigned a crucial role to MVBs in Notch signaling that critically relies on its multi-vesicular morphology\cite{24}.

Samuel Liégeois et al. showed that mutations in H+-ATPase (V-ATPase) that is required for exosome and morphogen (Hedgehog-related) release in C. elegans led to accumulation of MVBs and impaired larval development\cite{25}. Before entry into MVBs most (RTK) receptors are activated at the plasma-membrane by ligand-binding and are subsequently endocytosed (internalized) into early endosomes\cite{26}. The vesicular-mediated transport of receptors from the plasma membrane is considered to lower the amount of receptors exposed on the cell’s surface thereby controlling signalling strength. Recent findings however suggest this is only partly true, and focus is now shifting towards endosomal vesicles themselves as important platforms for initiation, elongation, and termination of receptor signalling\cite{27}.

Joffre et al. showed that Met, the receptor for Hepatocyte Growth Factor (HGF), requires endocytosis for downstream activation of its pathway. Strikingly, the transforming phenotype of a tumour-associated Met-activating mutation was inhibited by an endocytosis inhibitor, while maintaining its activation status\cite{28}. Taken together, accumulating evidence now shows that not the mere presence of signaling molecules in subcellular membranes determines signaling, but that association within specific localized microdomains plays a prominent role\cite{29}.

In addition, endocytosis and subsequent loading into MVBs of non-RTK signaling complexes such as the Wnt/GSK3 receptor complex for instance, is critical for Wnt-signalling. However, here GSK3 is a negative regulator that is excluded from its cytosolic substrates such as β-catenin\cite{30}. In light of the recent findings by Chairoungdua et al, MVBs may play a dual role in the regulation of Wnt signalling. It is unclear whether Wnt/GSK3 receptor complex containing MVBs function as temporary storage or whether they are destined for secretion or lysosomal degradation\cite{30}. (Figure 1)

**LMP1 trafficking and signalling**

It was long presumed that LMP1, being a mimic of the surface receptor CD40 localizes to and signals from the plasma membrane. Yet mutants that are directed specifically to the plasma membrane, do not reveal increased signalling potency. One deletion mutant of LMP1 that lacks the first two trans-membrane regions of LMP1 (ΔTM1-2

**
LMP1) is prominently present in the PM. ΔTM1-2 LMP1 is devoid of a putative lipid-raft anchoring domain ‘FWLY’ and seems to preferentially accumulate in the plasma membrane (Figure 3a) compared to wild type LMP1. Accordingly, expression of WT-LMP1 in HEK293 cells leads to a ~30% decrease in CD63 surface levels (SD 0.08%) measured by FACS, while this was not seen with ΔTM1-2 LMP1 (95%; SD 1.37%) (Figure 3b). Since we do not observe much LMP1 protein without CD63 in vesicles at the ER/Golgi region, we reason that LMP1 probably associates with CD63 before reaching the plasma membrane. What could be a biological explanation for LMP1 mimicking CD40 signaling from intracellular compartments rather than the plasma membrane? Being a ligand-independent receptor there seems no apparent need for LMP1 to traffic to the surface, as opposed to EGFR (Figure 1, in red) or CD40. It is more likely that LMP1 is transported away from the Golgi, directly to MVBs. Indeed we and others found that endogenous LMP1 accumulates in ILVs of MVBs1,31 (Figure 2). In fact, endogenous LMP1 is hardly detected at all on the surface of B cells. However, if LMP1 is rapidly internalized via lipid-rafts, it remains possible that the plasma membrane has a role in LMP1 physiology (Figure 1). Ultimately however, endogenous and exogenously expressed LMP1 are sorted into endosomes and exosomes for secretion, raising the important question, why LMP1 seems preferentially secreted instead of being degraded?

Conclusion

Future questions that need to be addressed regarding the incorporation of signalling proteins into the endo-exosomal pathway are plentiful. What would be the benefit of secretion instead of degradation of proteins, in controlling signalling? A logical answer could be that secreted proteins serve an additional purpose after binding and/or uptake by recipient cells. Indeed, Wnt is known to be transferred trans-synaptically via exosomes and is able to signal In Trans32. In this scenario the protein is actively sorted and secreted in exosomes. Taken together, current in vitro findings support a new concept for receptor regulation via shared trafficking with tetraspanins in the endosomal-exosomal pathway, involving defined subdomains of palmitoylated proteins, tetraspanins and certain lipids. A challenge for the future would be to translate these models into in vivo studies and defining a role for exosome secretion of signalling intermediates in health and disease.

REFERENCES


